DOCSLIB.ORG

EMJ-Respiratory-8.1-2020-1.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EMJ-Respiratory-8.1-2020-1.Pdf RESPIRATORY European Edition Vol. 8.1 November 2020 emjreviews.com + ERS INTERNATIONAL CONGRESS 2020 + EDITOR’S PICK + INTERVIEWS Two ERS 2020 Award Winners Improving Antenatal provide fascinating insights into their area of expertise in Asthma Management: cardiopulmonary rehabilitation A Complex Journey and intensive care medicine. + ABSTRACT REVIEWS Captivating reviews of abstracts presented at ERS International Congress 2020. WELCOME TO THE BREATHING HOTSPOT. Visit www.wehale.life/hcp GO TO DESTINATION FOR HEALTHCARE PROFESSIONALS WORKING WITH ASTHMA AND COPD • Patient support materials • Instruction and tutorial videos • Information about the Easyhaler® product family ENTER CHECK THE LATEST SCIENTIFIC INSIGHTS Terapia wziewna – ze szczególnym uwzględnieniem steroidów – w okresie pandemii COVID-19. Scientific Presentations at Virtual ERS Congress 2020 Performance under simulated www.wehale.life/de/Corona/ Sponsored by Orion Pharma. real-life conditions. Cercano al inhalador ideal: fácil y conveniente. (NL) Switching asthma and COPD patients to Easyhaler® Potilaiden tyytyväisyys inhalaattoriin Costs of switching to low global warming leads to improved clinical outcomes and QOL. on yhteydessä parempaan hoitomyönty- potential inhalers. UK Prescribing Information (FR) Pharmacokinetics of salmeterol and fluticasone vyyteen ja astman hoitotasapainoon. propionate delivered in combination via Easyhaler® Evaluation of the efficiency of single-inhaler and Diskus® dry powder inhalers. combination therapy with budesonide/ Adverse events should be reported. formoterol fumarate in patients with Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300. CORP-EASYH-991/09-2020 bronchial asthma in daily clinical practice. June2020/EASYH-830/ Contents + EDITORIAL BOARD 6 + WELCOME 9 + FOREWORD 11 + CONGRESS REVIEW Review of the European Respiratory Society (ERS) International 12 Congress 2020, 6th–9th September + SYMPOSIUM REVIEWS The Treatment of Severe Respiratory Disorders in Challenging Times 26 Successful Inhalation Therapy in 2020: Patients and Inhalers in Focus 35 Importance of Detecting Wheezing in Young Children to Minimise 44 Asthma Exacerbation + POSTER REVIEWS Dupilumab in Moderate-to-Severe Asthma: Updates from the ERS 50 International Congress 2020 Dupilumab Improves Outcomes for Patients with Severe Chronic 57 Rhinosinusitis with Nasal Polyps Irrespective of the Number of Surgeries and the Time Since Surgery or Diagnosis + ABSTRACT REVIEWS 65 + CONGRESS INTERVIEW Dina Brooks and Greet Van den Berghe 84 4 RESPIRATORY • November 2020 EMJ “Always open access, always at the forefront; please enjoy the following pages, and I hope that this content adds value to your medical practice, whatever your role in the field.” Spencer Gore, CEO + INTERVIEW Sore Throat Treatment Guidelines are Fanning the Flames of 90 Antimicrobial Resistance Martin Duerden + FEATURE Loose ENDs: Electronic Nicotine Delivery Systems and the FDA’s 93 Recent Enforcement Policy Ahmad et al. + ARTICLES Editor’s Pick: Improving Antenatal Asthma Management: 97 A Complex Journey Chen et al. Spatiotemporal Cellular Networks Maintain Immune Homeostasis in 108 the Lung Borger Risk Factors for Severe Coronavirus Disease (COVID-19) 120 Hussain et al. Effects of Noninvasive Versus Invasive Mechanical Ventilation on Sleep 127 in the Intensive Care Unit – A Pilot Study Ugurlu et al. Cryobiopsy In Flexi-Rigid Pleuroscopy in a Region with Low 137 Mesothelioma Prevalence Nyanti et al. Creative Commons Attribution-Non Commercial 4.0 November 2020 • RESPIRATORY 5 Editorial Board Editor-in-Chief Dr Antonio Rossi IQVIA, Milan, Italy Editorial Board Dr Martin Balzan University of Malta, Malta Prof Peter Barnes Imperial College London, UK Dr Catharina Belge University Hospitals Leuven, Belgium Prof Dr Jacques Bouchard Université Laval, Canada, and CIUSSS Capitale-Nationale, Canada Prof Andrew Bush Imperial College London, UK Prof Giorgio Walter Canonica Humanitas Research Hospital, Italy Prof Enrico Clini University of Modena, Italy Prof Dr Oliver Eickelberg University of Colorado Anschutz Medical Campus, USA Dr Atul Gupta King's College London, UK Prof Dr Nicholas Hill Tufts Medical Center, USA Dr Neil Holden University of Lincoln, UK Dr Islam Ibrahim University of California, USA Dr Ravi Kalhan Northwestern University Feinberg School of Medicine, USA Prof Dario Olivieri University of Parma, Italy Dr Joanna Porter University College London Hospital, UK Dr Paraschiva Postolache Grigore T. Popa University of Medicine and Pharmacy, Romania Prof Mohammad Azizur Rahman Dhaka University, Dhaka, Bangladesh VIEW IN FULL 6 RESPIRATORY • November 2020 EMJ Aims and Scope We are always keen to hear from healthcare professionals wishing to discuss potential submissions, please email: EMJ is an online only, peer-reviewed, open access general [email protected] journal, targeted towards readers in the medical sciences. We aim to make all our articles accessible to readers from To submit a paper, use our online submission site: any medical discipline. www.editorialmanager.com/e-m-j EMJ allows healthcare professionals to stay abreast of Submission details can be found through our website: key advances and opinions across Europe. www.emjreviews.com/contributors/authors EMJ aims to support healthcare professionals in continuously developing their knowledge, effectiveness, Reprints and productivity. The editorial policy is designed to All articles included in EMJ are available as reprints encourage discussion among this peer group. (minimum order 1,000). Please contact [email protected] if you would like to order reprints. EMJ is published quarterly and comprises review articles, case reports, practice guides, theoretical discussions, and original research. Distribution and Readership EMJ also publishes 16 therapeutic area journals, which EMJ is distributed through controlled circulation to provide concise coverage of salient developments at healthcare professionals in the relevant fields the leading European congresses. These are published across Europe. annually, approximately 6 weeks after the relevant congress. Further details can be found on our website: Indexing and Availability www.emjreviews.com EMJ is indexed on DOAJ, the Royal Society of Medicine, and Google Scholar®; selected articles are indexed in Editorial Expertise PubMed Central®. EMJ is supported by various levels of expertise: EMJ is available through the websites of our leading • Guidance from an Editorial Board consisting of leading partners and collaborating societies. authorities from a wide variety of disciplines. EMJ journals are all available via our website: • Invited contributors are recognised authorities from www.emjreviews.com their respective fields. • Peer review, which is conducted by EMJ’s Peer Review Open Access Panel as well as other experts appointed due to their This is an open-access journal in accordance with the knowledge of a specific topic. Creative Commons Attribution-Non Commercial 4.0 • An experienced team of editors and technical editors. (CC BY-NC 4.0) license. Peer Review Congress Notice On submission, all articles are assessed by the editorial Staff members attend medical congresses as reporters team to determine their suitability for the journal and when required. appropriateness for peer review. Editorial staff, following consultation with either a This Publication member of the Editorial Board or the author(s) if ISSN 2054-3166 necessary, identify three appropriate reviewers, who are selected based on their specialist knowledge in the EMJ Respiratory is published once relevant area. a year. For subscription details please visit: www.emjreviews.com All peer review is double blind. All information obtained by EMJ and each of the Following review, papers are either accepted without contributions from various sources is as current and modification, returned to the author(s) to incorporate accurate as possible. However, due to human or required changes, or rejected. mechanical errors, EMJ and the contributors cannot guarantee the accuracy, adequacy, or completeness of Editorial staff have final discretion over any any information, and cannot be held responsible for proposed amendments. any errors or omissions. EMJ is completely independent of the review event (ERS 2020) and the use of the Submissions organisations does not constitute endorsement or media partnership in any form whatsoever. We welcome contributions from professionals, consultants, academics, and industry leaders on relevant Front cover and contents photograph: and topical subjects. Vienna, Austria. © vichie81 / 123rf.com We seek papers with the most current, interesting, and relevant information in each therapeutic area and accept original research, review articles, case reports, and features. Creative Commons Attribution-Non Commercial 4.0 November 2020 • RESPIRATORY 7 EMJ Respiratory 8.1 Chairman of Advisory Board Head of Operations Prof Jonathan Sackier Keith Moule Chief Executive Officer Operations Assistants Spencer Gore Satkartar Chagger, Emma Knight Chief Commercial Officer Editor Daniel Healy Evgenia Koutsouki Chief Operations Officer Deputy Managing Editor Dan Scott Sam Davis Head of Publishing Content Manager Hamish Dickie Kirstie Turner Head of Content Marketing Editorial Assistants Sen Boyaci Lenos Archer-Diaby, Michaila Byrne, Katherine Colvin, Rachel Donnison, Anaya Malik, Isabel Head of Commercial O’Brien,
Load more

Recommended publications
  • Gender Equity Post-COVID-19
    ISeptembermmunology 2020 | ISSN 1356-5559 (print) News Gender equity post-COVID-19: coordinating our efforts to preserve diversity UK Coronavirus The UK Our first fully Immunology Immunological Open Access Consortium: Toolbox: journal Immunotherapy bringing immunology a hub for veterinary www.immunology.org together immunological reagents Advances 2 ADVERTISEMENTS 1 CytoFLEX, Kaluza and Duraclone are for research use only. Not for diagnostic purposes. All other products identifi ed are not for use in diagnostic procedures. The CytoFLEX, MET ONE 3400, PAT700, Multisizer 4e, Vi-CELL XR, Vi-CELL MetaFLEX, and Kaluza are designed to support GMP compliance. The Multisizer 4e, Vi-CELL XR, and Vi-CELL MetaFLEX are for Laboratory Use Only. © 2018 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. T-Cell_Anzeige_190x129mm_2.indd 1 26.03.20 11:59 Known for quality and reliability, InvivoGen provides cutting-edge tools Take your research to the research community worldwide to the next level InvivoGen’s innovative products: TLRs & innate immunity PRR ligands Reporter cell lines Inhibitors Antibodies & vaccination Mycoplasma detection & elimination Selective antibiotics COVID-19 Cloning and expression vectors Genes and promoters Custom services More information: www.invivogen.com Immunology News | September 2020 A WORD FROM THE EDITOR 3 ©©Shutterstock/howcolour Welcome to the autumn issue of Immunology This new issue also features an overview of News. Here, we look back at what we’ve been the impact of COVID-19 on gender inequity. doing to continue supporting our members Members from the Australian and New and feeding into public discussion around Zealand Society for Immunology provide COVID-19, including our three webinar a perspective from Societies, EMCRs and series and our new infographics on PCR educators, and how we can plan for the future.
    [Show full text]
  • Editorial: the Role of Innate Lymphoid Cells in Mucosal Immunity
    EDITORIAL published: 17 June 2020 doi: 10.3389/fimmu.2020.01233 Editorial: The Role of Innate Lymphoid Cells in Mucosal Immunity Jessica G. Borger 1*†, Graham Le Gros 2† and Joanna R. Kirman 3† 1 Department of Immunology and Pathology, Central Clinical School, Monash University, Alfred Research Alliance, Melbourne, VIC, Australia, 2 Allergic & Parasitic Diseases Programme, Malaghan Institute of Medical Research, Wellington, New Zealand, 3 Department of Microbiology & Immunology, University of Otago, Dunedin, New Zealand Keywords: ILC, NK cell, mucosal, immunity, lung, gastrointestinal tract, genitourinary tract Editorial on the Research Topic The Role of Innate Lymphoid Cells in Mucosal Immunity Innate Lymphoid Cells (ILCs) are tissue-resident innate cells that are deeply integrated within mucosal tissues and play a critical role in tissue homeostasis and inflammatory processes. The collection of articles in this Frontiers Research Topic investigates and discusses the new and emerging roles of ILCs in mucosal immunity. The field of ILC biology has increased exponentially in recent years. Although the scientific Edited and reviewed by: community had been aware of the existence of certain innate cells of lymphoid origin for many Marina Cella, Washington University School of years, it has only been in the past decade that the full extent of the ILC family and their Medicine in St. Louis, United States wide-reaching biological roles has been recognized. As the field expanded, to avoid confusion due to the different names being used in the literature for the same ILC subsets, in 2013 it was *Correspondence: Jessica G. Borger proposed that ILCs should be divided into three broad lineages based on specific transcription [email protected] factor expression and the cytokines they produce.
    [Show full text]
  • Type 3 Ilcs in Lung Disease
    REVIEW published: 29 January 2019 doi: 10.3389/fimmu.2019.00092 Type 3 ILCs in Lung Disease Amanda Ardain 1,2, James Zachary Porterfield 1,2,3, Henrik N. Kløverpris 1,4,5 and Alasdair Leslie 1,5* 1 Africa Health Research Institute, Durban, South Africa, 2 College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa, 3 Yale School of Public Health, Yale University, New Haven, CT, United States, 4 Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark, 5 Department of Infection and Immunity, University College London, London, United Kingdom The lungs represent a complex immune setting, balancing external environmental signals with a poised immune response that must protect from infection, mediate tissue repair, and maintain lung function. Innate lymphoid cells (ILCs) play a central role in tissue repair and homeostasis, and mediate protective immunity in a variety of mucosal tissues, including the lung. All three ILC subsets are present in the airways of both mice and humans; and ILC2s shown to have pivotal roles in asthma, airway hyper-responsiveness, and parasitic worm infection. The involvement of ILC3s in respiratory diseases is less well-defined, but they are known to be critical in homeostasis, infection and inflammation at other mucosal barriers, such as the gut. Moreover, they are important players in the IL17/IL22 axis, which is key to lung health. In this review, we discuss the emerging role of ILC3s in the context of infectious and inflammatory lung diseases, with a focus on data from human subjects. Keywords: ILC3, lung disease, pnemonia, tuberulosis, COPD, airway hypersensitivity, pulmonary fibrosis Edited by: Jessica Borger, Monash University, Australia INTRODUCTION Reviewed by: The lungs are complex organs, the proper functioning of which is essential for good health, William Garrow Kerr, but whose exposure to the external environment renders them susceptible to infections and Upstate Medical University, United States environmental toxins.
    [Show full text]
  • GSH-C4 Acts As Anti-Inflammatory Drug in Different Models of Canonical and Cell Autonomous Inflammation Through Nfκb Inhibition
    ORIGINAL RESEARCH published: 06 February 2019 doi: 10.3389/fimmu.2019.00155 GSH-C4 Acts as Anti-inflammatory Drug in Different Models of Canonical and Cell Autonomous Inflammation Through NFκB Inhibition Dolores Limongi 1†, Sara Baldelli 1†, Paola Checconi 1, Mariaelena Marcocci 2, Giovanna De Chiara 3, Alessandra Fraternale 4, Mauro Magnani 4, Maria Rosa Ciriolo 5,6* and Anna Teresa Palamara 6,7* 1 Department of Human Sciences and Promotion of the Quality of Life, IRCCS San Raffaele Pisana, San Raffaele Roma Open University, Rome, Italy, 2 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, 3 Institute of Translational Pharmacology, National Research Council Rome, Rome, Italy, 4 University of Urbino Carlo Bo, Department of Biomolecular Sciences, Urbino, Italy, 5 Department of Biology, University of Rome “Tor Vergata”, Rome, Italy, 6 7 Edited by: IRCCS San Raffaele Pisana, Rome, Italy, Institute Pasteur-Fondazione Cenci Bolognetti, Rome, Italy Stefano Caserta, University of Hull, United Kingdom An imbalance in GSH/GSSG ratio represents a triggering event in pro-inflammatory Reviewed by: cytokine production and inflammatory response. However, the molecular mechanism(s) Valerio Chiurchiù, Campus Bio-Medico University, Italy through which GSH regulates macrophage and cell autonomous inflammation remains Jessica Borger, not deeply understood. Here, we investigated the effects of a derivative of GSH, the Monash University, Australia N-butanoyl glutathione (GSH-C4), a cell permeable compound, on lipopolisaccharide *Correspondence: Maria Rosa Ciriolo (LPS)-stimulated murine RAW 264.7 macrophages, and human macrophages. LPS [email protected] alone induces a significant production of pro-inflammatory cytokines, such as IL-1β, Anna Teresa Palamara IL-6, and TNF-α and a significant decrement of GSH content.
    [Show full text]
  • Group 2 Innate Lymphoid Cells Are Redundant in Experimental Renal Ischemia-Reperfusion Injury
    UCSF UC San Francisco Previously Published Works Title Group 2 Innate Lymphoid Cells Are Redundant in Experimental Renal Ischemia- Reperfusion Injury. Permalink https://escholarship.org/uc/item/9pb8c94q Authors Cameron, Guy JM Cautivo, Kelly M Loering, Svenja et al. Publication Date 2019 DOI 10.3389/fimmu.2019.00826 Peer reviewed eScholarship.org Powered by the California Digital Library University of California ORIGINAL RESEARCH published: 16 April 2019 doi: 10.3389/fimmu.2019.00826 Group 2 Innate Lymphoid Cells Are Redundant in Experimental Renal Ischemia-Reperfusion Injury Guy J. M. Cameron 1,2, Kelly M. Cautivo 3, Svenja Loering 1,2, Simon H. Jiang 4,5, Aniruddh V. Deshpande 1,2,6, Paul S. Foster 1,2, Andrew N. J. McKenzie 7, Ari B. Molofsky 3, Philip M. Hansbro 1,2,8,9 and Malcolm R. Starkey 1,2* 1 Priority Research Centre’s GrowUpWell and Healthy Lungs, School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia, 2 Hunter Medical Research Institute, New Lambton Heights, NSW, Australia, 3 Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States, 4 Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australia National University, Canberra, ACT, Australia, 5 Department of Renal Medicine, The Canberra Hospital, Canberra, ACT, Australia, 6 The John Hunter Children’s Hospital, New Lambton Heights, NSW, Australia, 7 MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, 8 Centre for inflammation, Centenary Institute, Sydney, NSW, Australia, 9 Faculty of Science, University of Technology, Ultimo, NSW, Australia Acute kidney injury (AKI) can be fatal and is a well-defined risk factor for the development of chronic kidney disease.
    [Show full text]
  • Contact Us Derrick Rowley Medal Asi Honours Susanne
    ASI NEWS MARCH 2020 CONTACT US 10 26 AUSTRALIAN AND NEW ZEALAND SOCIETY FOR DERRICK ROWLEY MEDAL VISIT FROM PROF. IMMUNOLOGY INC. ASI HONOURS SUSANNE STEVEN ALBELDA ASI INC. SECRETARIAT HEINZEL AND ALAN BAXTER FROM UNIVERSITY OF PO BOX 1371, PENNSYLVANIA MITCHAM NORTH 3132 CONNIE JACKAMAN PH: 03 8393 9388 ALEC REDWOOD immunology.org.au/contact-us CONTENTS ASI NEWSLETTER MARCH 2020 CONTENTS PRESIDENT’S COLUMN ....................................... 3 SPECIAL INTEREST GROUP NEWS ..................20 John Fraser Helen McGuire A COUNTRY, A COMMUNITY NOOSA THROUGH THE MUCOSA AND BURNING BRIGHT ................................................ 4 MICROBIOME .....................................................21 Angelica Lau Jonatan Leffler ASI MEETING HIGHLIGHTS.................................. 5 LET’S TALK ABOUT EDUCATION IN IMMUNOLOGY ................................................... 23 HELLO FROM YOUR NEW Samy Sakkal HON. SECRETARY ................................................ 7 Connie Jackaman UPCOMING VISITING SPEAKERS IN 2020 ...... 25 Stuart Mannering 2019 TREASURER’S REPORT .............................. 7 Asolina Braun PROF. STEVEN ALBELDA FROM UNIVERSITY OF PENNSYLVANIA VISITS ASI COMMUNITY ....... 26 CTI SPECIAL FEATURES ...................................... 8 Alec Redwood DERRICK ROWLEY MEDAL HONORS ITA - 2019 ASI ANNUAL MEETING, ADELAIDE, SUSANNE HEINZEL & ALAN BAXTER ...............10 AUSTRALIA ........................................................ 28 Connie Jackaman Amania A. Sheikh THE IUIS CORNER ................................................11
    [Show full text]
  • Contact Us Hear from the Newly Formed ASI Special Interest Groups
    ASI NEWS March 2021 WIN a signed copy of ‘Pandemics’ by Nobel laureate Peter Doherty 6 Find out the ways ASI is helping to keep you connected 11 26 Contact Us Australian and New Zealand Hear from the newly Launch of the Clinical Society for Immunology Inc. formed ASI Special & Translational ASI Inc. Secretariat Interest Groups Immunology COVID-19 PO Box 1371, Mitcham North 3132 Fernando Fonseca Guimaraes collection Ph: 03 8393 9388 immunology.org.au/contact-us Contents ASI Newsletter March 2021 Contents HELLO AND WELCOME TO 2021 ...................................................................................................................................................................3 Debbie Burnett SECRETARY REPORT ........................................................................................................................................................................................4 Connie Jackaman TREASURER’S REPORT ....................................................................................................................................................................................5 Asolina Braun WIN YOUR OWN AUTOGRAPHED COPY OF PETER DOHERTY’S BOOK, “PANDEMICS” .................................................................6 Immunology & Cell Biology and Clinical & Translational Immunity ASI ADVANCED IMMUNOLOGY SCHOOL ....................................................................................................................................................7 AIS Organising Committee A MESSAGE
    [Show full text]
  • ILC2 Orchestration of Local Immune Function in Adipose Tissue
    Edinburgh Research Explorer ILC2 orchestration of local immune function 1 in adipose tissue Citation for published version: Benezech, C & Jackson-Jones, L 2019, 'ILC2 orchestration of local immune function 1 in adipose tissue', Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.00171 Digital Object Identifier (DOI): 10.3389/fimmu.2019.00171 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Frontiers in Immunology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 04. Oct. 2021 MINI REVIEW published: 07 February 2019 doi: 10.3389/fimmu.2019.00171 ILC2 Orchestration of Local Immune Function in Adipose Tissue Cécile Bénézech 1* and Lucy Helen Jackson-Jones 2* 1 BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, 2 Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom ILC2s were originally identified as IL-5 and IL-13 secreting “natural helper cells” present within the fat-associated lymphoid clusters of the mesenteries in both mouse and man.
    [Show full text]
  • Young Investigator Symposium Series 2020 PRELIMINARY PROGRAM – SUBJECT to CHANGE
    Young Investigator Symposium Series 2020 PRELIMINARY PROGRAM – SUBJECT TO CHANGE Young Investigator Symposium Series 2020 FRIDAY 2 OCTOBER - PRELIMINARY PROGRAM – SUBJECT TO CHANGE www.viin.org.au #viinyis Young Investigator Symposium Series 2020 PRELIMINARY PROGRAM – SUBJECT TO CHANGE Program-at-a-Glance 2020 Monday 12 October: 10am – 12.45pm Keynote speaker: Associate Professor Kimberley Kline, Nanyang Technological University, Singapore Talks selected from abstracts Technical workshop Daily prize announcement Tuesday 13 October: 10am – 12pm Grant writing workshop and Q&A • Dr Sant-Rayn Pasricha, Walter and Eliza Hall Institute • Dr Sally Roberts, veski • Associate Professor Meredith O’Keeffe, Monash University and ARC College of Experts • Associate Professor Michelle Tate, Hudson Institute of Medical Research and NHMRC Career Development Fellow • Professor James Beeson, Burnet Institute Tuesday 13 October: 1pm – 2.30pm Concurrent E-poster sessions (I and II) Tuesday 13 October: 7pm – 8.15pm Art in Science evening • Marta de Menezes • Science Gallery Melbourne Wednesday 14 October: 10am – 12pm Careers panel and Q&A • Dr Krystal Evans • Dr Jessica Borger • Dr Michael Christie • Dr Stephanie Tan • Dr Ariel Achtman Wednesday 14 October: 1pm – 2.30pm Concurrent E-poster sessions (III and IV) Thursday 15 October: 10am – 12.45pm Keynote speaker: Dr Amy Chung, Peter Doherty Institute of Infection and Immunity, University of Melbourne Talks selected from abstracts Technical workshop Daily prize announcement Friday 16 October: 10am – 1pm Keynote
    [Show full text]
  • Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients
    ORIGINAL RESEARCH published: 06 September 2019 doi: 10.3389/fimmu.2019.02121 Peripheral Innate Lymphoid Cells Are Edited by: Jessica Borger, Increased in First Line Metastatic Monash University, Australia Reviewed by: Colorectal Carcinoma Patients: A Ennio Carbone, Università degli studi Magna Græcia di Negative Correlation With Th1 Catanzaro, Italy Anja Fuchs, Immune Responses Washington University in St. Louis, United States Romain Loyon 1†, Marine Jary 2,3,4, Bérengère Salomé 1†, Alejandra Gomez-Cadena 1, *Correspondence: Jeanne Galaine 2, Marie Kroemer 2,5, Pedro Romero 1, Sara Trabanelli 1, Olivier Adotévi 2,3, Camilla Jandus Christophe Borg 2,3 and Camilla Jandus 1* [email protected] 1 Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, †Present address: Lausanne, Switzerland, 2 Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Romain Loyon, Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France, 3 Department of Medical Oncology, University Univ. Bourgogne Franche-Comté, Hospital of Besançon, Besançon, France, 4 INSERM CIC-1431, Clinical Investigation Center in Biotherapy, University Hospital INSERM, EFS BFC, UMR1098, of Besançon, Besançon, France, 5 Department of Pharmacy, University Hospital of Besançon, Besançon, France Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, Several distinct innate lymphoid cell (ILC) populations have been recently identified and France; Department of Medical Oncology, University Hospital of shown to play a critical role in the immediate immune defense. In the context of tumors, Besançon, Besançon, France there is evidence to support a dual role for ILCs with pro- or antitumor effects, depending Bérengère Salomé, on the ILC subset and the type of cancer.
    [Show full text]
  • Innate Lymphoid Cells in Helminth Infections—Obligatory Or Accessory?
    REVIEW published: 10 April 2019 doi: 10.3389/fimmu.2019.00620 Innate Lymphoid Cells in Helminth Infections—Obligatory or Accessory? Stephan Löser 1, Katherine A. Smith 2,3 and Rick M. Maizels 1* 1 Wellcome Centre for Integrative Parasitology, Institute of Infection, Immunology and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2 Cardiff Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, 3 Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa ILCs burst onto the immunological scene with their involvement in bacterial and helminth infections. As their influence has emerged, it has become clear that they play a fundamental role in regulating barrier tissue homeostasis and the immune response during inflammation. A subset of ILCs, ILC2s, has become the focus of attention for many helminth biologists—stepping into the limelight as both the elusive initiator and amplifier of the type-2 response. In many of the early reports, conclusions as to their function were based on experiments using unadapted parasites or immune-compromised hosts. In this review we re-examine the generation and function of type-2 ILCs in helminth infection and the extent to which their roles may be essential or redundant, in both primary and challenge infections. ILC2s will be discussed in terms of a broader innate network, which when in dialogue with adaptive immunity, allows the generation of the anti-parasite response. Finally, we will review how helminths manipulate ILC2 populations Edited by: Jessica Borger, to benefit their survival, as well as dampen systemic inflammation in the host, and how Monash University, Australia this understanding may be used to improve strategies to control disease.
    [Show full text]
  • Innate Lymphoid Cells in Mucosal Immunity Santosh K
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2019 Innate lymphoid cells in mucosal immunity Santosh K. Panda Marco Colonna Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs REVIEW published: 07 May 2019 doi: 10.3389/fimmu.2019.00861 Innate Lymphoid Cells in Mucosal Immunity Santosh K. Panda and Marco Colonna* Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States Innate lymphoid cells (ILCs) are innate counterparts of T cells that contribute to immune responses by secreting effector cytokines and regulating the functions of other innate and adaptive immune cells. ILCs carry out some unique functions but share some tasks with T cells. ILCs are present in lymphoid and non-lymphoid organs and are particularly abundant at the mucosal barriers, where they are exposed to allergens, commensal microbes, and pathogens. The impact of ILCs in mucosal immune responses has been extensively investigated in the gastrointestinal and respiratory tracts, as well as in the oral cavity. Here we review the state-of-the-art knowledge of ILC functions in infections, allergy and autoimmune disorders of the mucosal barriers. Keywords: ILCs, NK cells, mucosal infections, COPD, IBD – Inflammatory bowel diseases, allergy and asthma INTRODUCTION ILCs are a family of lymphocytes comprising the innate counterparts of T cells. They are poised to secrete cytokines that respond swiftly to pathogenic tissue damage and shape subsequent Edited by: Jessica Borger, adaptive immunity (1). While lacking antigen-specific receptors, ILCs detect changes in the Monash University, Australia microenvironment through receptors for cytokines that are released upon tissue damage, as well as a broad range of receptors for nutrient components, microbial products, lipid mediators, and Reviewed by: Ya-Jen Chang, neuronal transmitters.
    [Show full text]